PHARMACY

Campaign seeks to raise awareness of inflammatory bowel disease

BY Alaric DeArment

NEW YORK — An organization focused on inflammatory bowel disease has enlisted a star of "NYPD Blue," "Judging Amy" and "Private Practice" to raise awareness of the condition.

The Crohn’s and Colitis Foundation of America hired actress Amy Brenneman, who has ulcerative colitis, one of two diseases that collectively make up IBD; the other is Crohn’s disease. Both conditions are autoimmune diseases that cause discomfort and inflammation of the intestines and require frequent trips to the bathroom.

The CCFA also launched an ad campaign, Escape the Stall, which includes ads showing various people in restroom stalls in order to raise awareness that IBD can affect anyone.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Use of generics would save money, study finds

BY Alaric DeArment

WASHINGTON — A new study indicates that the public bears "unnecessary expense" when generic drugs aren’t used.

The study, published Monday in JAMA Internal Medicine, found that prescribing branded drugs when generics are available "generates unnecessary medical expenditures, the costs of which are borne by the public in the form of higher copayments, increased health insurance costs, and higher Medicare and Medicaid expenses," the authors, led by Harvard Medical School professor Eric Campbell, wrote.

"The JAMA Internal Medicine study demonstrates that we are still leaving savings on the table that could be achieved by increasing the use of generic drugs," said Ralph Neas, president and CEO of the Generic Pharmaceutical Association, an industry lobbying group. "The use of safe and effective generic versions of brandname drugs currently saves consumers and the U.S. healthcare system $1 billion every other day, a total of $192 billion in 2011. But, as significant as these savings are, there still is room for improvement, and we must realize that generics are part of the solution to sustaining affordable healthcare in America."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

S.HAWKINS says:
Oct-17-2013 08:47 am

You and me both... it was a very interesting study by the way. Poor people shouldn't suffer like that when it comes to health.

jhonson101 says:
Feb-11-2013 10:53 pm

I actually agree with this study. Some of the Doctors prescribed those expensive medicine where in there are generics available. how about those poor people who has limited money, how can they afford such expensive medicine. I hope Doctor's could be able to find solution for this, try to considers those poor family.

TRENDING STORIES

PHARMACY

Abbott spins off new drug company

BY Alaric DeArment

NEW YORK — Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company’s leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.

AbbVie’s product portfolio includes drugs like the autoimmune drug Humira (adalimumab), the testosterone-replacement drug AndroGel, the prostate cancer drug Lupron (leuprolide acetate), the lung infection drug Synagis (palivizumab) and others. The company’s pipeline includes more than 20 mid- to late-stage clinical programs in areas like hepatitis C, rheumatoid arthritis, psoriasis, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, spondyloarthropathies, multiple myeloma and endometriosis.

"Today, AbbVie launches with an outstanding portfolio, a solid pipeline and enthusiastic people who will serve patients and deliver growth," AbbVie CEO and chairman Richard Gonzalez said. "With those assets and a relentless focus on innovation, we intend to create significant value for our shareholders."

The company, headquartered in North Chicago, Ill., will include 21,000 employees around the world — including Gonzalez, EVP business development, external affairs and general counsel Laura Schumacher, and EVP and CFO William Chase.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES